SARTF (Sartorius AG) Beneish M-Score: -2.84 (As of Jun. 24, 2026)


SARTF Sartorius AG SARTF
85 GF Score
Price $192.43
GF Value $226.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sartorius AG Beneish M-Score?

Sartorius AG SARTF -1.83% 85 Beneish M-Score is -2.84 as of Jun. 24, 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Sartorius AG ranks better than 70.85% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.84 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sartorius AG's Beneish M-Score or its related term are showing as below:

SARTF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.07   Med: -2.66   Max: -2.29
Current: -2.84

During the past 13 years, the highest Beneish M-Score of Sartorius AG was -2.29. The lowest was -3.07. And the median was -2.66.


Sartorius AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Beneish M-Score Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.32 -2.91 -2.94 -3.02

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -2.92 -2.98 -3.02 -2.84

SARTF vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Sartorius AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Beneish M-Score falls into.


SARTF
85GF Score
Sartorius AG SARTF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sartorius AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9041+0.528 * 0.9932+0.404 * 1.0087+0.892 * 1.1142+0.115 * 1.022
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9615+4.679 * -0.07013-0.327 * 0.9825
=-2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $351 Mil.
Revenue was 1039.422 + 1086.183 + 989.671 + 1019.954 = $4,135 Mil.
Gross Profit was 479.191 + 463.934 + 461.62 + 480.046 = $1,885 Mil.
Total Current Assets was $2,224 Mil.
Total Assets was $11,413 Mil.
Property, Plant and Equipment(Net PPE) was $2,847 Mil.
Depreciation, Depletion and Amortization(DDA) was $492 Mil.
Selling, General, & Admin. Expense(SGA) was $1,031 Mil.
Total Current Liabilities was $2,443 Mil.
Long-Term Debt & Capital Lease Obligation was $3,858 Mil.
Net Income was 64.971 + 109.133 + 21.479 + 37.486 = $233 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 218.382 + 381.733 + 260.094 + 173.241 = $1,033 Mil.
Total Receivables was $349 Mil.
Revenue was 954.595 + 949.529 + 880.799 + 926.48 = $3,711 Mil.
Gross Profit was 465.946 + 413.194 + 383.019 + 417.976 = $1,680 Mil.
Total Current Assets was $2,335 Mil.
Total Assets was $10,932 Mil.
Property, Plant and Equipment(Net PPE) was $2,575 Mil.
Depreciation, Depletion and Amortization(DDA) was $457 Mil.
Selling, General, & Admin. Expense(SGA) was $962 Mil.
Total Current Liabilities was $1,602 Mil.
Long-Term Debt & Capital Lease Obligation was $4,541 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(351.214 / 4135.23) / (348.649 / 3711.403)
=0.084932 / 0.09394
=0.9041

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1680.135 / 3711.403) / (1884.791 / 4135.23)
=0.452695 / 0.455789
=0.9932

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2223.584 + 2846.821) / 11412.832) / (1 - (2334.595 + 2574.703) / 10932.216)
=0.555728 / 0.550933
=1.0087

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4135.23 / 3711.403
=1.1142

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(456.899 / (456.899 + 2574.703)) / (492.448 / (492.448 + 2846.821))
=0.150712 / 0.147472
=1.022

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1030.822 / 4135.23) / (962.211 / 3711.403)
=0.249278 / 0.259258
=0.9615

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3857.919 + 2443.006) / 11412.832) / ((4541.297 + 1601.514) / 10932.216)
=0.552091 / 0.5619
=0.9825

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(233.069 - 0 - 1033.45) / 11412.832
=-0.07013

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sartorius AG has a M-score of -2.78 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.84 mean?
Sartorius AG (SARTF) has a Beneish M-Score of -2.84 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius AG and its competitors. According to the industry distribution chart, Sartorius AG ranks #223 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 29.2%.
Is Sartorius AG's Beneish M-Score too high?
Sartorius AG's current Beneish M-Score is -2.84. Based on the distribution chart, Sartorius AG ranks #223 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #223 out of 765 companies for Beneish M-Score. This puts Sartorius AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius AG and its competitors. Sartorius AG's current Beneish M-Score is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Beneish M-Score is -2.84. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Beneish M-Score is -2.84 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SARTF:

  • Beneish M-Score: -2.84
  • GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score

Get the complete analysis for SARTF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$192.43
Price
$226.12
GF Value